Those that target CD47 (e.g., CD47 activating antibodies or SIRPγ:CD47 bi-specific antibodies) would likely be preferable for two key reasons: 1) SIRPγ:CD47 signaling occurs unilaterally downstream of CD47, and 2) the T1D-risk associated SNPs tagged to SIRPG are predicted to promote reduced SIRPγ expression and/or interaction with CD47 (5, 6, 20, 31, 35). The gene discussed is SIRPG; the disease is type 1 diabetes mellitus.